These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 525439)

  • 1. Disopyramide plasma levels in cardiac patients on maintenance therapy.
    Landmark K; Storstein L; Larsen A
    Acta Med Scand; 1979; 206(5):385-9. PubMed ID: 525439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma disopyramide concentrations following a 300-mg oral loading dose in acute myocardial infarction.
    Weissberg PL; Matenga J; Hayler AM; Holt DW
    Ther Drug Monit; 1982; 4(3):277-80. PubMed ID: 7135457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antiarrhythmic action of disopyramide: a study of plasma levels].
    Page A; Pic A; Besse P
    Arch Mal Coeur Vaiss; 1979 Jul; 72(7):774-80. PubMed ID: 117775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute oral antiarrhythmic testing with disopyramide.
    García-Barreto D; Toruncha A; Gonzalez-Gomez A; Llerena L; Groning E; Hernandez-Cañero A
    Clin Cardiol; 1981; 4(6):330-5. PubMed ID: 7326884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral disopyramide dosage regimes in ischaemic heart disease.
    Bryson SM; Fotheringham GH; Struthers MG; Whiting B
    J Clin Hosp Pharm; 1982 Mar; 7(1):37-42. PubMed ID: 7096577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged variability in plasma protein binding of disopyramide after acute myocardial infarction.
    David BM; Ilett KF; Whitford EG; Stenhouse NS
    Br J Clin Pharmacol; 1983 Apr; 15(4):435-41. PubMed ID: 6849779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentration of disopyramide given as capsules and controlled release tablets.
    Arnman K; Graffner C; Rikner L; Ryden L; Voog L
    Eur J Clin Pharmacol; 1983; 24(2):199-203. PubMed ID: 6840167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum drug concentrations and adverse effects in cardiac patients after administration of a new controlled-release disopyramide preparation.
    Zema MJ
    Ther Drug Monit; 1984; 6(2):192-8. PubMed ID: 6740739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disopyramide kinetics in patients with acute myocardial infarction.
    Ilett KF; Madsen BW; Woods JD
    Clin Pharmacol Ther; 1979 Jul; 26(1):1-7. PubMed ID: 445953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative bioavailability of disopyramide after multiple dosing with standard capsules and controlled-release tablets.
    Forssell G; Graffner C; Nordlander R; Nyquist O
    Eur J Clin Pharmacol; 1980; 17(3):209-13. PubMed ID: 7363933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of an anti-arrhythmic agent, disopyramide, in delayed action form ('Ritmoforine' Retard).
    Nauta IL; van de Calseyde JF
    Curr Med Res Opin; 1981; 7(4):215-26. PubMed ID: 7226872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of hemodynamic and electrocardiographic changes following intravenous disopyramide.
    Hulting J; Rosenhamer G
    Acta Med Scand; 1979; 205(5):417-23. PubMed ID: 443082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.
    Lien E; Bakke OM
    Br J Clin Pharmacol; 1983 Jul; 16(1):71-6. PubMed ID: 6882625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma concentrations and protein binding of disopyramide and mono-N-dealkyldisopyramide during chronic oral disopyramide therapy.
    Aitio ML
    Br J Clin Pharmacol; 1981 Apr; 11(4):369-75. PubMed ID: 7259930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from intravenous to oral slow-release disopyramide in acute myocardial infarction.
    Zannad F; Royer-Morrot MJ; Zakari I; Sadoul N; Royer RJ
    Fundam Clin Pharmacol; 1987; 1(3):219-24. PubMed ID: 3428841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disopyramide plasma concentrations following single and multiple doses of the immediate- and controlled-release capsules.
    Karim A; Schubert EN; Burns TS; Palmer M; Zinny MA
    Angiology; 1983 Jun; 34(6):375-92. PubMed ID: 6346960
    [No Abstract]   [Full Text] [Related]  

  • 17. The pharmacokinetics of disopyramide following myocardial infarction with special reference to oral and intravenous dose regimens.
    Ward JW; Kinghorn GR
    J Int Med Res; 1976; 4(1 Suppl):49-53. PubMed ID: 1026529
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum disopyramide concentrations and suppression of ventricular premature contractions.
    Ueda CT; Dzindzio BS; Vosik WM
    Clin Pharmacol Ther; 1984 Sep; 36(3):326-36. PubMed ID: 6467792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy of ventricular tachyarrhythmia with disopyramid phosphate].
    Steinbrunn W; Mattmann H; Enrico JF; Engel U
    Schweiz Med Wochenschr; 1980 Jun; 110(24):953-7. PubMed ID: 7414314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma levels of disopyramide after administration of conventional capsules and sustained-release tablets.
    Nauta IL; van de Calseyde J; Hertzberger DP
    Curr Med Res Opin; 1983; 8(8):582-93. PubMed ID: 6653136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.